Australia now has four CGRP monoclonal antibodies for migraine — Emgality, Ajovy and Vyepti are PBS-subsidised for chronic migraine, while Aimovig is registered but private only. Dr Ron Granot explains how each works, PBS eligibility, what to expect, and how CGRP compares with Botox in 2026.